Praxis Precision Medicines, Inc. Common Stock
PRAX
$327.68
+4.17%
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on translating genetic insights into therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company leverages its proprietary Cerebrum and Solidus platforms to develop a diversified pipeline targeting movement disorders and epilepsy, including candidates like Ulixacaltamide and Relutrigine. As a precision medicine pioneer in neurology, Praxis stands out for its multimodal CNS portfolio and genetic-driven approach. The current investor narrative centers on the FDA's acceptance of its drug application for essential tremor, which has driven a massive stock surge, alongside strong institutional backing and the potential for a 2027 approval that could unlock a multi-billion-dollar market opportunity.…
PRAX
Praxis Precision Medicines, Inc. Common Stock
$327.68
Related headlines
PRAX 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Praxis Precision Medicines, Inc. Common Stock's 12-month outlook, with a consensus price target around $425.98 and implied upside of +30.0% versus the current price.
Average Target
$425.98
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$262 - $426
Analyst target range
Praxis is covered by 15 analysts, with a consensus leaning bullish: ratings include multiple Buy/Outperform ratings from firms like Baird, Truist, Guggenheim, Needham, HC Wainwright, Piper Sandler, and BTIG, while Wedbush maintains an Underperform and Wells Fargo has an Equal Weight. The average EPS estimate is $52.30, with a low of $14.85 and high of $96.69, reflecting wide dispersion. The average revenue estimate is $3.48 billion, with a range of $1.56 billion to $5.75 billion, implying massive expected sales from the pipeline. The implied upside/downside from the current price of $324.99 to the average target is not directly calculable from the data, but the bullish consensus suggests significant upside potential. The target range is wide: the low EPS estimate of $14.85 implies a potential downside scenario (e.g., pipeline setbacks or slower adoption), while the high of $96.69 reflects optimistic assumptions of blockbuster sales and multiple expansion. The spread between low and high estimates indicates high uncertainty, typical for pre-revenue biotechs. Recent ratings have been stable, with no major downgrades, and institutional investors have increased stakes (e.g., a $266 million fund investment). The wide target range underscores the binary nature of the stock—success could lead to massive gains, while failure could result in substantial losses.
Drowning in data?
Find the real signal!
PRAX Technical Analysis
Praxis stock is in a powerful long-term uptrend, with a 1-year price change of +546.1%, dramatically outperforming the S&P 500's +20.6% gain. The current price of $324.99 sits at 88.7% of its 52-week range ($37.19–$366.52), indicating the stock is near its highs and reflecting strong momentum. This positioning suggests bullish sentiment but also raises caution about potential overextension, as the stock has already priced in significant optimism. Short-term momentum shows a mixed picture: the 1-month change is +35.0%, accelerating sharply, while the 3-month change is a modest +2.8%. The divergence between the explosive 1-month rally and the tepid 3-month performance suggests a recent catalyst-driven surge (likely the FDA acceptance) that may have temporarily outpaced the underlying trend. The stock's beta of 2.76 indicates it is 176% more volatile than the S&P 500, amplifying both upside and downside risks. Key support lies near the 52-week low of $37.19, while resistance is at the 52-week high of $366.52. A breakout above $366.52 would signal a continuation of the uptrend, while a breakdown below recent support near $250 (the June 2026 low) could indicate a trend reversal. The high beta underscores the need for careful position sizing.
Beta
2.76
2.76x market volatility
Max Drawdown
-36.3%
Largest decline past year
52-Week Range
$37-$367
Price range past year
Annual Return
+511.3%
Cumulative gain past year
| Period | PRAX Return | S&P 500 |
|---|---|---|
| 1m | +22.9% | +1.4% |
| 3m | -3.6% | +7.4% |
| 6m | +10.1% | +8.6% |
| 1y | +511.3% | +20.3% |
| ytd | +14.4% | +10.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PRAX Fundamental Analysis
Praxis is a pre-revenue biotech with zero revenue in the most recent quarter (Q4 2025), though it reported $7.5 million in revenue in Q4 2024 from an option exercise fee. The company's growth trajectory is entirely dependent on pipeline advancement and regulatory milestones, with no product sales to date. The recent FDA acceptance of its essential tremor drug application is a pivotal catalyst that could lead to commercialization in 2027, but until then, revenue remains negligible. The company is deeply unprofitable, with a net loss of -$88.9 million in Q4 2025 and a trailing twelve-month net income of -$303.3 million. Gross margin is negative (-$28,000 gross profit on zero revenue), reflecting the cost of clinical trials and R&D. Operating expenses, primarily R&D ($77.5 million in Q4 2025) and SG&A ($19.5 million), continue to drive losses. The net loss has widened from -$58.7 million in Q4 2024, indicating increasing cash burn as the pipeline advances. Praxis maintains a strong balance sheet with $357.3 million in cash as of Q4 2025, supported by recent equity raises ($613.3 million in common stock issued in Q4 2025). The debt-to-equity ratio is negligible at 0.000125, indicating no significant debt. However, free cash flow is deeply negative at -$249.5 million TTM, and the company relies on external financing to fund operations. The current ratio of 10.22 suggests ample liquidity, but the cash burn rate implies a finite runway unless additional funding is secured or revenue materializes.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-249499000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PRAX Overvalued?
Since Praxis has negative net income and negative EBITDA, we use the price-to-sales (PS) ratio for valuation. However, with zero revenue in recent quarters, the PS ratio is effectively undefined (0), making traditional valuation metrics challenging. The trailing PE is -21.86x and forward PE is -34.51x, both meaningless due to losses. The EV/EBITDA of -20.70x also reflects negative earnings. Given the lack of revenue, valuation is better assessed through pipeline potential and comparable biotech deals. Peer comparison is limited as most biotech peers with similar stage assets also lack revenue. Historically, Praxis's PS ratio (when revenue existed) was extremely high (e.g., 206x in Q4 2024 on minimal revenue), indicating the market priced in significant future sales. The current market cap of $9.14 billion implies a high expectation for the essential tremor program and pipeline, which could justify a premium if approved. The stock's historical PE range has been deeply negative, reflecting persistent losses. The current PB ratio of 7.55x is near the high end of its historical range (0.67x–7.55x over the past three years), suggesting the market is pricing in optimistic future profitability. This elevated multiple relative to history indicates that the stock is not a value play but rather a high-risk, high-reward bet on regulatory and commercial success.
PE
-21.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -19x~0x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-20.7x
Enterprise Value Multiple
